Subscribe
manjurul
manjurul / iStockphoto.com
13 July 2017Americas

Bill Gates venture and GE sign malaria licensing deal with Access Bio

A collaboration between Bill Gates and Intellectual Ventures (IV), in partnership with conglomerate GE, has signed a licensing deal with US diagnostics technology company Access Bio to make and sell tools for “rapidly” identifying asymptomatic malaria.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
MPP inks deal with French pharma firm to fight malaria in low-income countries
15 September 2022   Malaria remains endemic in 91 countries representing half of the world’s population | Licence is key to allow rapid access to innovation for those who need it most.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Big Pharma
MPP inks deal with French pharma firm to fight malaria in low-income countries
15 September 2022   Malaria remains endemic in 91 countries representing half of the world’s population | Licence is key to allow rapid access to innovation for those who need it most.

More on this story

Big Pharma
MPP inks deal with French pharma firm to fight malaria in low-income countries
15 September 2022   Malaria remains endemic in 91 countries representing half of the world’s population | Licence is key to allow rapid access to innovation for those who need it most.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages